This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
by Zacks Equity Research
Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on the same.
Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA
by Zacks Equity Research
The FDA accepts Novartis' (NVS) BLA seeking approval for brolucizumab for the treatment of wet AMD.
Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran
by Zacks Equity Research
Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic porphyria.
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
by Ekta Bagri
We take a look at companies, which have been developing treatments for various diseases using RNAi technology.
Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More
by Zacks Equity Research
Key highlights of the past week are new drug approvals, collaborations and pipeline updates.
Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics
by Zacks Equity Research
Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).
Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up
by Zacks Equity Research
Inovio's (INO) investigational HPV therapy, INO-3106, achieves the clinical efficacy for treating patients with recurrent respiratory papillomatosis, an HPV-associated disease. Shares up.
Allergan's AMD Drug Lowers Inflammation in Phase III Study
by Zacks Equity Research
Allergan's (AGN) MAPLE study evaluating a 12-week dose of abicipar pegol demonstrates decreased intraocular inflammation in nAMD patients.
Inovio Closes Enrollment in Brain Cancer Study Before Time
by Zacks Equity Research
Inovio (INO) concludes enrollment in the phase I/II study on INO-5401+INO-9012 combined with Regeneron/Sanofi's Libtayo for the newly-diagnosed subjects with glioblastoma prior to the scheduled date.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.
Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth
by Zacks Equity Research
Inovio's (INO) most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.
10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run
by Sweta Killa
Though most of the stocks in the S&P 500 ETF have delivered astounding returns during the decade, a few were the real stars, skyrocketing more than 2000%.
Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News
by Zacks Equity Research
Key highlights of the past week are regulatory and pipeline developments.
Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down
by Zacks Equity Research
Inovio Pharmaceuticals (INO) reports results for fourth quarter of 2018 wherein loss and revenues both miss estimates.
Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion
by Zacks Equity Research
The FDA approves a label expansion of Regeneron's (REGN) asthma drug, Dupixent for moderate-to-severe atopic dermatitis in adolescents.
Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.
Regeneron (REGN) Up 0.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More
by Zacks Equity Research
Key highlights of the past week are merger agreements plus regulatory and pipeline developments.
Regeneron-Sanofi Get CHMP Nod for Dupixent Label Expansion
by Zacks Equity Research
The CHMP gives a positive opinion for the label expansion of Regeneron (REGN) and Sanofi's Dupixent for the treatment of asthma in Europe.
Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates
by Zacks Equity Research
Key highlights of the past week are merger agreements, and regulatory and pipeline developments.
Sanofi/Regeneron Disagree With Jury Verdict in Amgen's Favor
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron (REGN) disagree with a jury verdict in favor of Amgen upholding the validity of two patents related to Repatha.
bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
bluebird (BLUE) reports narrower-than-expected Q4 loss. The pipeline progress looks encouraging.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study
by Zacks Equity Research
Pfizer (PFE) and Eli Lilly (LLY) announce that the higher dose of their investigational pain candidate, tanezumab, significantly reduces chronic low back pain in a late-stage study.